The European Medicines Agency has launched an initiative to improve the predictability of new drug applications, given that only around 30-40% of planned marketing authorization applications (MAAs) are submitted for evaluation on time every year, while the rest are either postponed or withdrawn.
While the EMA usually asks companies to provide a rationale when changing their submission dates or withdrawing submissions, the agency told the Pink Sheet that under the new exercise it would become “more systematic” in requesting this information and in chasing companies in case of “no-shows